Production (Stage)
OnKure Therapeutics, Inc.
OKUR
$2.88
$0.020.70%
NASDAQ
| 03/31/2025 | 12/31/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 3.99M | 4.11M | 3.59M | 1.27M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 17.00M | 17.85M | 14.34M | 9.83M | |
| Operating Income | -17.00M | -17.85M | -14.34M | -9.83M | |
| Income Before Tax | -15.93M | -17.44M | -14.14M | -9.54M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -15.93M | -17.44M | -14.14M | -9.54M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -15.93M | -17.44M | -14.14M | -9.54M | |
| EBIT | -17.00M | -17.85M | -14.34M | -9.83M | |
| EBITDA | -16.88M | -17.74M | -14.23M | -9.72M | |
| EPS Basic | -1.19 | -1.37 | -1.06 | -30.37 | |
| Normalized Basic EPS | -0.74 | -0.81 | -0.66 | -18.98 | |
| EPS Diluted | -1.19 | -1.37 | -1.06 | -30.37 | |
| Normalized Diluted EPS | -0.74 | -0.81 | -0.66 | -18.98 | |
| Average Basic Shares Outstanding | 13.42M | 12.77M | 13.37M | 314.00K | |
| Average Diluted Shares Outstanding | 13.42M | 12.77M | 13.37M | 314.00K | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |